Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 219

The DOI matches its Crossref record.

Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial

Poynard, T., Imbert‐Bismut, F., Ratziu, V., Chevret, S., Jardel, C., Moussalli, J., Messous, D., Degos, F., for the GERMED cyt04 group · 2002 · Journal of Viral Hepatitis

Abstract

A liver fibrosis index was recently prospectively validated in a cross‐sectional study where patients infected by hepatitis C virus (HCV) had only one biopsy and no longitudinal follow‐up. The aim of this study was to retrospectively assess the diagnostic value of this index in patients included in a randomized trial of interferon (IFN) using repeated measurements, two biopsies and hyaluronic acid as a comparative reference. One‐hundred and sixty‐five patients who had had two interpretable liver biopsies and at least one stored serum sample before IFN treatment were selected. Seventy‐eight patients received 3 M U of IFN‐α thrice weekly for 24 weeks and 87 followed a reinforced regimen for 48 weeks. A fibrosis index combining five biochemical markers (α2‐macroglobulin, haptoglobin, apolipoprotein A1, γ‐glutamyl transpeptidase (GGT) and total bilirubin adjusted for gender and age) as well as hyaluronic acid was assessed on 461 samples available at baseline, at the end of treatment and at the end of follow‐up (72 weeks). There was a significant decrease of the fibrosis index score among the 17 sustained virologic responders, from 0.33 ± 0.06 (mean ± SE) at baseline to 0.18 ± 0.06 at 72 weeks in comparison with 92 nonresponders (from 0.41 ± 0.03 at baseline to 0.44 ± 0.03 at 72 weeks; P < 0.001) and in comparison with 56 relapsers (from 0.36 ± 0.03 at baseline to 0.32 ± 0.03 at 72 weeks; P=0.05). No significant differences were observed for hyaluronic acid. Hence, this fibrosis index could be used as a surrogate marker of the antifibrotic effect of treatments in patients with chronic hepatitis C.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2893.2002.00341.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 219

Metadata

Authors
Poynard, T., Imbert‐Bismut, F., Ratziu, V., Chevret, S., Jardel, C., Moussalli, J., Messous, D., Degos, F., & for the GERMED cyt04 group
Venue
Journal of Viral Hepatitis
Publisher
Wiley
Published
2002-03
Volume
9
Issue
2
Pages
128-133
ISSN
  • 1352-0504 (ISSN-L)
  • 1365-2893
OpenAlex
W2087928833
Cited by
219
References
0
FWCI
10.58
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. https://app.cochat.ai/papers/10.1046/j.1365-2893.2002.00341.x
The paper
Poynard, T., Imbert‐Bismut, F., Ratziu, V., Chevret, S., Jardel, C., Moussalli, J., Messous, D., Degos, F., & for the GERMED cyt04 group. (2002). Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. Journal of Viral Hepatitis. https://doi.org/10.1046/j.1365-2893.2002.00341.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.